CIK 0001517681 · Non-accelerated filer<br>Smaller reporting company
Propanc Biopharma, Inc.
Sign in to watch- Ticker
- PPCB
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Jun 30
- Incorporated
- DE
- Entity type
- operating
- EIN
- 330662986
- Phone
- 61-03-9882-0780
- Business address
- 302/6 BUTLER STREET, CAMBERWELL, VICTORIA, Australia, 3124
- Former names
- Propanc Health Group Corp
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-07-05 | ZELINGER JOSEF Director | Grant or award · Common Stock Purchase Warrant | +15,000,000 | 15,000,000 | ||
| 2021-08-17 | Kenyon Julian Norman Chief Scientific Officer | Grant or award | +3,420,000 | 3,420,005 | ||
| 2021-08-17 | Nathanielsz James Andrew CEO/CFO | Grant or award | +5,928,000 | 5,928,004 | ||
| 2021-08-17 | Nathanielsz James Andrew CEO/CFO | Grant or award | +2,800,000 | 2,800,000 | ||
| 2019-05-14 | Kenyon Julian Norman Chief Scientific Officer | Grant or award · Stock Options (Right to Buy) | +9,750,000 | 9,750,000 | ||
| 2019-05-14 | Kenyon Julian Norman Chief Scientific Officer | Grant or award · Restricted Stock Units | +9,750,000 | 9,750,000 | ||
| 2019-05-14 | Kenyon Julian Norman Chief Scientific Officer | Grant or award · Restricted Stock Units | +9,750,000 | 9,750,000 | ||
| 2019-05-14 | Nathanielsz James Andrew CEO, Acting CFO, Chairman | Grant or award · Stock Options (Right to Buy) | +19,500,000 | 19,500,000 | ||
| 2019-05-14 | Nathanielsz James Andrew CEO, Acting CFO, Chairman | Grant or award · Restricted Stock Units | +19,500,000 | 19,500,000 | ||
| 2019-05-14 | Nathanielsz James Andrew CEO, Acting CFO, Chairman | Grant or award · Restricted Stock Units | +19,500,000 | 19,500,000 | ||
| 2016-04-14 | Nathanielsz James Andrew CEO, CFO, Secretary, Treasurer | Grant or award · Stock Option (Right to Buy) | +71,500,000 | 71,500,000 | ||
| 2016-04-14 | Kenyon Julian Norman Director | Grant or award · Stock Option (Right to Buy) | +71,500,000 | 71,500,000 | ||
| 2015-02-04 | Nathanielsz James Andrew CEO, CFO, Secretary, Treasurer | Other acquisition | +33,259,350 | 42,711,111 | ||
| 2015-02-04 | Kenyon Julian Norman Director | Other acquisition | +17,654,470 | 28,466,534 | ||
| 2014-11-09 | Nathanielsz James Andrew Chief Executive Officer | Grant or award · Series A Preferred Stock | +500,000 | 500,000 | ||
| 2013-07-05 | Nathanielsz James Andrew Chief Executive Officer | Sale | −55,000 | $0.09 | $5K | 9,701,761 |
| 2013-01-23 | Nathanielsz James Andrew Chief Executive Officer | Sale | −15,000 | $0.20 | $3K | 9,756,761 |
| 2012-12-13 | Nathanielsz James Andrew Chief Executive Officer | Sale | −5,500 | $0.20 | $1K | 9,771,761 |
| 2012-09-14 | Nathanielsz James Andrew Chief Executive Officer | Sale | −5,000 | $0.20 | $1K | 9,777,261 |
| 2012-09-04 | Nathanielsz James Andrew Chief Executive Officer | Sale | −250,000 | $0.20 | $50K | 9,782,261 |
Page 1 of 2 · 21 trades